Quantcast

Dilon Technologies’ Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities

February 3, 2009

NEWPORT NEWS, Va., Feb. 3 /PRNewswire/ — Dilon Technologies, Inc., a
leader in molecular breast imaging, today announced the release of two new
collimators: the Slant15 Collimator for breast imaging and the Low Energy
High-Resolution (LEHR) Collimator. Both collimators are attachment options for
the Dilon 6800 Gamma Camera that help to optimize imaging for the respective
applications.

The Slant15 Collimator is a 15-degree slant parallel-hole collimator that
minimizes the dead space along the edge of the detector, allowing better
visualization of the chest wall in breast imaging. Uses include: breast
imaging; sentinel node imaging; thyroid imaging; and parathyroid imaging.

LEHR collimator is a high-resolution collimator for general nuclear
medicine applications. Uses include thyroid imaging, parathyroid imaging,
sentinel node imaging, spot bone imaging, gall bladder ejection, and pediatric
imaging studies.

“With the release of these new collimators, we are expanding breast
imaging and general nuclear applications for the Dilon 6800 Gamma,” said Bob
Moussa
, President and CEO of Dilon Technologies. “This is another step in
providing a broader service offering to clinicians.”

About Dilon Technologies

Dilon Technologies, Inc. is bringing innovative new medical imaging
products to market. Dilon’s cornerstone product, the Dilon 6800, is a
high-resolution, small field-of-view gamma camera, optimized to perform BSGI,
a molecular breast imaging procedure which images the metabolic activity of
breast lesions through radiotracer uptake. Many leading medical centers around
the country are now offering BSGI to their patients, including: Cornell
University
Medical Center, New York; George Washington University Medical
Center, Washington, D.C.; and The Rose, Houston.

For more information on Dilon Technologies please visit
http://www.dilon.com.

SOURCE Dilon Technologies, Inc.


Source: newswire



comments powered by Disqus